Loading
Sacituzumab tirumotecan is Kelun-Biotech's TROP2 ADC, approved in China in 2024 for pretreated triple-negative breast cancer and then EGFR-mutant lung cancer. Merck holds rights outside Greater China and runs the TroFuse programme of more than ten phase 3 trials across breast, lung, endometrial and cervical cancer; in the US it holds a priority voucher but no approval yet.
Kelun-Biotech's sac-TMT was approved by China's NMPA in 2024 for pretreated TNBC (the first TROP2 ADC approval in China) and later for EGFR-mutant NSCLC. Merck holds ex-Greater-China rights and runs the TroFuse programme of >10 phase 3 trials, including first-line TNBC (positive on primary endpoint per 2026 reports), HR+ breast, NSCLC, endometrial, and cervical cancer, many combined with pembrolizumab. FDA Breakthrough Therapy designation (EGFR-mutant NSCLC, 2024) and a Commissioner's National Priority Voucher (July 2026).
Sac-TMT carries T030, a belotecan-derived TOP1 inhibitor; belotecan shown.
Anti-TROP2 IgG1 with a stable, irreversibly-conjugated linker and a belotecan-derived TOP1 payload with reported lower efflux-pump susceptibility. Connects to TROP2.
1.Antibody binds TROP2 on the tumour cell surface
Source: www.frontiersin.org/journals/oncology-reviews/articles/10.3389/or.2026.1781533/full. Doses are for orientation; the current label governs.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2022-05 | Sichuan Kelun-Biotech to Merck & Co. (MSD) Sacituzumab tirumotecan (SKB264, MK-2870), TROP2 ADC | Licence | $47m | up to $1.4bn | source |
Compare all products across the US, EU, UK, Japan, China and Australia →
Merck licenses ex-Greater-China rights (deal expanded December 2022) source
NMPA approval, pretreated advanced TNBC (OptiTROP-Breast01); first TROP2 ADC approved in China source
Breakthrough Therapy designation, EGFR-mutant NSCLC after TKI source
EGFR-mutant NSCLC after TKI failure source
Commissioner's National Priority Voucher (CNPV) awarded source
| Region | Year | Indication |
|---|---|---|
| China | 2024 | Pretreated advanced TNBC; later EGFR-mutant NSCLC after TKI |
| Adverse event |
|---|
| Neutropenia |
| Anaemia |
| Stomatitis |
| Nausea |
| Alopecia |
Most common grade ≥3 event in OptiTROP-Breast01; rates per publication. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| China | NMPA approved 2024; National Reimbursement Drug List inclusion from 2025 | not disclosed | - |
| United States | Investigational; not yet approved | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Sacituzumab tirumotecan" OR ABSTRACT:"Sacituzumab tirumotecan" OR TITLE:"sac-TMT" OR ABSTRACT:"sac-TMT" OR TITLE:"MK-2870" OR ABSTRACT:"MK-2870" OR TITLE:"SKB264" OR ABSTRACT:"SKB264") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sacituzumab tirumotecan, not a curated reading list.
Shares TROP2 PET → TROP2 ADC selection, TROP2 expression, Topoisomerase-I inhibitor payloads, TROP2 PET to choose and sequence TROP2 ADCs.
Shares TROP2 PET → TROP2 ADC selection, TROP2 expression, Topoisomerase-I inhibitor payloads, TROP2 PET to choose and sequence TROP2 ADCs.
Shares TROP2 PET to choose and sequence TROP2 ADCs, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, HER2-low and HER2-ultralow metastatic breast cancer.
Shares T030 (belotecan derivative), Hydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing), Efflux-agnostic therapy for mesenchymal TNBC, Topoisomerase-I inhibitor payloads.
Shares A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F), Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06), Topoisomerase-I inhibitor payloads, Metastatic triple-negative breast cancer.
Shares TROP2 PET to choose and sequence TROP2 ADCs, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, HER2-low and HER2-ultralow metastatic breast cancer.
Shares TROP2 PET to choose and sequence TROP2 ADCs, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Metastatic triple-negative breast cancer.
Shares TROP2 PET to choose and sequence TROP2 ADCs, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Metastatic triple-negative breast cancer.